title: The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials.
abstract: OBJECTIVE
  While gynaecological cancer patients who participate in Phase I clinical trials are not routinely considered for elective surgery because of a short life expectancy, this should not be overlooked in carefully selected responding patients.
  
  
  RESULTS
  We describe two cases of patients with different gynaecological cancers, who received treatment within separate phase I trials, and who then proceeded to surgical resection of their cancers, resulting in complete remission.
  
  
  CONCLUSIONS
  Surgery, when feasible, should be taken into consideration as a potential management option, even when patients are receiving treatment within a phase I trial.
authors.affiliation: Drug Development Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, UK.
authors.forename: J
authors.initials: J
authors.lastname: Vitfell-Pedersen
authors.forename: T A
authors.initials: TA
authors.lastname: Yap
authors.forename: V
authors.initials: V
authors.lastname: Moreno
authors.forename: R D
authors.initials: RD
authors.lastname: Baird
authors.forename: A Z
authors.initials: AZ
authors.lastname: Khan
authors.forename: D P J
authors.initials: DP
authors.lastname: Barton
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
mesh_terms: D000231:Adenocarcinoma, Papillary / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000077716:Afatinib; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D017321:Clinical Trials, Phase I as Topic; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000601:surgery*; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D010386:Pelvic Neoplasms / Q000556:secondary / Q000601:surgery*; D010793:Phthalazines / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011799:Quinazolines / Q000008:administration & dosage; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D010793:Phthalazines; D010879:Piperazines; D011799:Quinazolines; D000068258:Bevacizumab; D000077716:Afatinib; D017239:Paclitaxel; C531550:olaparib